Results 81 to 90 of about 7,202 (139)

Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma. [PDF]

Am J Transl Res
Zhao W, Cheng X.
europepmc   +1 more source

Restricted Expression of the Constant Region 1 of T-Cell Receptor β by Flow Cytometry Facilitates Detection of T-Cell Neoplasms With High Specificity but Moderate Predictive Value. [PDF]

Eur J Haematol
Rajabian N, Axler O, Wistén E, Porwit A, Ehinger M.   +4 more
europepmc   +1 more source

Advanced Stage Hodgkin Lymphoma: A Review on Frontline Treatment Advances. [PDF]

Cancer J
Baron K, Hu B.
europepmc   +1 more source

Enhancement of CAR-T cell efficacy and persistence via CD30 costimulation and NF-κB signaling. [PDF]

Mol Cancer
Su Y, Yang G, Chen B, Qian Y, Ma W, Jiang X, Yu Q, Li Y, Xu L.   +8 more
europepmc   +1 more source

Efficacy of brentuximab vedotin combined with sintilimab in relapsed/refractory DLBCL patient with secondary hemophagocytic syndrome: a case report and literature review. [PDF]

Front Oncol
Cheng S, Wu H, Bao W, Peng Z, Huang F, Zhou S, Mo Q, Li Y, Bin Y, Lan D, Yang H.   +10 more
europepmc   +1 more source

Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease. [PDF]

NPJ Parkinsons Dis
Jaffery R, Zhao Y, Ahmed S, Schumacher JG, Ahn J, Shi L, Wang Y, Tan Y, Zhang J, Chen K, Tawbi H, Wang J, Schwarzschild MA, Peng W, Chen X.   +14 more
europepmc   +1 more source

Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics. [PDF]

J Pers Med
Casan JML, Ong XJ, van der Weyden C, Yannakou CK, Zhu J, D'Souza C, Neeson P, Prince HM.   +7 more
europepmc   +1 more source

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas. [PDF]

Am J Hematol
Stein H, Falini B.
europepmc   +1 more source

Multivalent aptamer engineered and functionalized NK cells for enhanced adoptive immunotherapy in CD30-positive malignant lymphoma. [PDF]

Mol Ther Nucleic Acids
Tan F, Wei R, Su J, Sheng C, Li Q, Long Y, Zhao X, Zhao L, Huang S, Zhang L, Yang L, Zhang H, Yang S, Li H.   +13 more
europepmc   +1 more source

Targeting macrophage-driven NK cell immunosuppression to improve cancer immunotherapy. [PDF]

J Immunother Cancer
Redavid AR, Cifaldi L, Bei R, De Billy E, Fruci D.   +4 more
europepmc   +1 more source